Close Menu

NEW YORK (GenomeWeb) – Startup mFluiDx — a portmanteau of "microfluidics" and "diagnostics" — is developing an inexpensive, sample-to-answer, self-digitizing quantitative microfluidic diagnostics platform that does not require an external instrument to run.

The mFludiX diagnostic is able to process whole blood with on-chip sample prep and requires simple external heating and a simple optical reader, similar to a DNA gel reader, to obtain quantitative results, mFluiDx co-founder Charlie Yeh said in an interview.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.

A genetic alteration appears to increase heart failure risk among people of African descent, according to the Washington Post.

In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."

In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.